Source comparison
International MOTS-c Legal Status Comparison
United States FDA / DEA Investigational biologic, unscheduled Yes No (outside approved trials) N/A. Not approved for prescription 503B pharmacies cannot compound; off-label use violates FFDCA European Union EMA Unapproved medicinal product Yes (under research
This comparison does not assign a generated winner or score.
- United States
- FDA / DEA
- Investigational biologic, unscheduled
- Yes
- No (outside approved trials)
- N/A. Not approved for prescription
- 503B pharmacies cannot compound; off-label use violates FFDCA
- European Union
- EMA
- Unapproved medicinal product
- Yes (under research exemptions)
- No
- N/A
- Falls under EU Clinical Trials Regulation for any human use
- United Kingdom
- MHRA
- Unlicensed medicine
- No (outside clinical trials)
- Possession legal; clinical administration requires trial authorization
- Australia
- TGA
- Unregistered therapeutic good
- Cannot be imported for personal use without TGA approval
- Canada
- Health Canada
- Investigational drug
- Requires Clinical Trial Application for human studies
- Japan
- PMDA
- Unapproved regenerative medicine product
- Stricter enforcement on peptides; limited research access
- The pattern is consistent: no major regulatory authority has approved MOTS-c for clinical use, but research procurement remains permissible across jurisdictions. Australia's TGA imposes the strictest import controls. Individuals cannot order MOTS-c for personal use even if framed as research, and customs seizures of peptide shipments increased 280% between 2023 and 2025. Canada permits research importation but requires institutional affiliation; wellness clinics cannot legally acquire MOTS-c for patient administration under Health Canada's framework.